Pneumonia as a trigger for atrial fibrillation

Nichols, Larry

doi:10.2185/jrm.2937

Cited by 4 publications

(5 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since diffuse lung infiltration is an indicator for more severe pneumonia, it may also be associated with a more prominent inflammatory state during the course of COVID-19. The pathophysiological mechanism may be a cytokine-mediated vasoconstriction that causes ischemia at the pulmonary venous atrial interface, where AF mostly occurs [ 28 ]. In addition to the increased inflammatory state, the further increase in endogenous catecholamine release and hemodynamic instability may also trigger AF.…”

Section: Discussionmentioning

confidence: 99%

New onset atrial fibrilation and risk faktors in COVID-19

Keleşoğlu

Yılmaz

Özkan

et al. 2021

Journal of Electrocardiology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

New onset atrial fibrilation and risk faktors in COVID-19

Keleşoğlu

Yılmaz

Özkan

et al. 2021

Journal of Electrocardiology

View full text Add to dashboard Cite

“…The pathologic explanation might be cytokine-induced vasoconstriction, which produces an ischemic state at the pulmonary venous atrial interface, which is where the majority of AFs develop. 26,34 Aside from the heightened inflammatory state, an upsurge in endogenous catecholamine secretion and also hemo- Notwithstanding, it is of essence to note that comparing NOAF patients with the control group of this cohort, the temperature on admission appeared subfebrile, and oxygen saturation reduced but not critically. However, the CURB-65 Score was moderate-high, and lung damage had been more significant in the AF group.…”

Section: Discussionmentioning

confidence: 95%

“…The pathologic explanation might be cytokine‐induced vasoconstriction, which produces an ischemic state at the pulmonary venous atrial interface, which is where the majority of AFs develop. 26 , 34 Aside from the heightened inflammatory state, an upsurge in endogenous catecholamine secretion and also hemodynamic imbalance might contribute to AF When pulmonary inflammation develops, gas exchange is disrupted, resulting in a ventilation/perfusion mismatch and, hence, hypoxemia. Consequently, widespread lung infiltration might induce hypoxemia, which might stand as another cause of NOAF in COVID‐19 patients.…”

Section: Discussionmentioning

confidence: 99%

“…Because widespread lung infiltration is a predictor of more severe pneumonia, it might be linked to a more pronounced inflammatory status throughout the COVID‐19 clinical course. The pathologic explanation might be cytokine‐induced vasoconstriction, which produces an ischemic state at the pulmonary venous atrial interface, which is where the majority of AFs develop 26,34 . Aside from the heightened inflammatory state, an upsurge in endogenous catecholamine secretion and also hemodynamic imbalance might contribute to AF When pulmonary inflammation develops, gas exchange is disrupted, resulting in a ventilation/perfusion mismatch and, hence, hypoxemia.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Risk factors, thromboembolic events, and clinical course of New‐Onset Atrial Fibrillation among COVID‐19 hospitalized patients: A multicenter cross‐sectional analysis in Iran

Rahimi

Afaghi

Tarki

et al. 2022

Health Science Reports

View full text Add to dashboard Cite

Background and Aims We focused on determining the risk factors, thromboembolic events, and clinical course of New‐Onset Atrial Fibrillation (NOAF) among hospitalized coronavirus disease (COVID‐19) patients. Methods This retrospective study was conducted in the major referral centers in Tehran, Iran. Of 1764 patients enrolled in the study from January 2020 until July 2021, 147 had NOAF, and 1617 had normal sinus rhythm. Univariate and multivariate Logistic regressions were employed accordingly to evaluate NOAF risk factors. The statistical assessments have been run utilizing SPSS 25.0 (SPSS) or R 3.6.3 software. Results For the NOAF patients, the age was significantly higher, and the more prevalent comorbidities were metabolic syndrome, heart failure (HF), peripheral vascular disease, coronary artery disease, and liver cirrhosis. The multivariate analysis showed the established independent risk factors were; Troponin‐I (hazard ratio [HR] = 3.86; 95% confidence interval [CI] = 1.89−7.87; p < 0.001), HF (HR = 2.54; 95% CI = 1.61−4.02; p < 0.001), bilateral grand‐glass opacification (HR = 2.26; 95% CI = 1.68−3.05; p = 0.002). For cases with thromboembolic events, NOAF was the most important prognostic factor (odds ratio [OR] = 2.97; 95% CI = 2.03−4.33; p < 0.001). While evaluating the diagnostic ability of prognostic factors in detecting NOAF, Troponin‐I (Area under the curve [AUC] = 0.85), C‐Reactive Protein (AUC = 0.72), and d ‐dimer (AUC = 0.65) had the most accurate sensitivity. Furthermore, the Kaplan‐Meier curves demonstrated that the survival rates diminished more steeply for patients with NOAF history. Conclusion In hospitalized COVID‐19 patients with NOAF, the risk of thromboembolic events, hospital stay, and fatality are significantly higher. The established risk factors showed that patients with older age, higher inflammation states, and more severe clinical conditions based on CHADS2VASC‐score potentially need subsequent preventive strategies. Appropriate prophylactic anticoagulants, Initial management of cytokine storm, sufficient oxygen support, and reducing viral shedding could be of assistance in such patients.

show abstract

“…Symptoms such as feeling ill, malaise or severe fatigue or weakness, and dyspnea are also seen in other flu and pneumonia. [ 60 61 62 ] Sore throat or pharyngalgia and rhinorrhea, Nasal congestion, sneezing and snotty nose, as well as rigor/chill are also nonspecific symptoms and have been reported with other influenza and common cold. [ 63 64 65 ]…”

Section: Discussionmentioning

confidence: 99%

Clinical manifestation, laboratory and radiology finding, treatment and outcomes of COVID-19

Nayeri

Nadali

Divani

et al. 2021

Journal of Research in Medical Sciences

View full text Add to dashboard Cite

Background: Since December 2019, coronavirus (COVID-19) spread throughout the world. The high rate of infection and its unknown nature led specialists to report the condition of patients. The aim of this study is to systematically review of symptoms, laboratory and radiologic findings, treatment, and outcomes of patients with COVID-19. Materials and Methods: Databases such as PubMed, Embase, Scopus, Web of Science, Google Scholar, and Cochrane were searched. Finally, 46 articles were appropriate for the aim of the study. After quality evaluation, the necessary data were extracted and meta-analysis was performed. Results: 4858 articles were retrieved until March 30, 2020. After screening, the full-text of 46 articles was assessed. Of the reported cases, 31.7% had no comorbidities, 21.4% had high blood pressure, 70.6% had fever, and lymphopenia was reported in 55.2% of patients. For 16% bilateral patchy shadowing in radiography and for 51% ground-glass opacity was reported. Outcomes were remarkable for recover to death. Conclusion: COVID-19 leads to healthcare problems for countries. Nonspecific symptoms have made it difficult for differential diagnoses without computed tomography-scan or corona Test, but they are not available in many countries. Therefore, this systematic review can help health care staff to make decisions based on symptoms, treatments, and outcomes..

show abstract

Pneumonia as a trigger for atrial fibrillation

Cited by 4 publications

References 12 publications

New onset atrial fibrilation and risk faktors in COVID-19

New onset atrial fibrilation and risk faktors in COVID-19

Risk factors, thromboembolic events, and clinical course of New‐Onset Atrial Fibrillation among COVID‐19 hospitalized patients: A multicenter cross‐sectional analysis in Iran

Clinical manifestation, laboratory and radiology finding, treatment and outcomes of COVID-19

Contact Info

Product

Resources

About